Rossella Manfredini

List of Publications by Year
in descending order

130	4,199	136950	123424
papers	citations	32 h-index	61 g-index

131	131	131	5507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
2	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	7.2	263
3	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108, 218-227.	1.4	226
4	Expression and Function of Nerve Growth Factor and Nerve Growth Factor Receptor on Cultured Keratinocytes. Journal of Investigative Dermatology, 1994, 103, 13-18.	0.7	165
5	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	1.4	115
6	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	3.2	111
7	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	1.4	105
8	Abundance of the primary transcript and its processed product of growth-related genes in normal and leukemic cells during proliferation and differentiation. Cancer Research, 1992, 52, 11-6.	0.9	99
9	c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood, 2010, 116, e99-e110.	1.4	95
10	Extracellular Purines Promote the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic Lineages. Stem Cells and Development, 2013, 22, 1097-1111.	2.1	95
11	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood, 2007, 109, 533-542.	1.4	93
12	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
13	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia, 2014, 28, 1811-1818.	7.2	75
14	Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Experimental Hematology, 2011, 39, 360-374.e5.	0.4	73
15	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 2007, 35, 1708.e1-1708.e12.	0.4	71
16	Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death and Differentiation, 2006, 13, 1686-1696.	11.2	67
17	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	7.2	66
18	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34â^' cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.	1.4	62

#	Article	IF	Citations
19	Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.. Journal of Experimental Medicine, 1993, 178, 381-389.	8.5	60
20	MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. Cell Death and Differentiation, 2015, 22, 1906-1921.	11.2	60
21	Genomic landscape of megakaryopoiesis and platelet function defects. Blood, 2016, 127, 1249-1259.	1.4	53
22	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood, 2012, 119, 217-226.	1.4	52
23	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget, 2017, 8, 49451-49469.	1.8	49
24	Expression of B7 Costimulatory Molecule in Cultured Human Epidermal Langerhans Cells Is Regulated at the mRNA Level. Journal of Investigative Dermatology, 1994, 103, 54-59.	0.7	48
25	miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. Nature Communications, 2019, 10, 5697.	12.8	48
26	Unravelling the Complexity of Inherited Retinal Dystrophies Molecular Testing: Added Value of Targeted Next-Generation Sequencing. BioMed Research International, 2016, 2016, 1-14.	1.9	47
27	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	1.4	47
28	The Kinetic Status of Hematopoietic Stem Cell Subpopulations Underlies a Differential Expression of Genes Involved in Self-Renewal, Commitment, and Engraftment. Stem Cells, 2005, 23, 496-506.	3.2	45
29	Noncoordinated expression of S6, S11, and S14 ribosomal protein genes in leukemic blast cells. Cancer Research, 1990, 50, 5825-8.	0.9	41
30	Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Leukemia, 2006, 20, 1751-1758.	7.2	38
31	Monocyte Distribution Width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients. Scientific Reports, 2021, 11, 12716.	3.3	38
32	All-trans-retinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells. Experimental Hematology, 1995, 23, 117-25.	0.4	38
33	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	1.4	34
34	miR-382-5p Controls Hematopoietic Stem Cell Differentiation Through the Downregulation of MXD1. Stem Cells and Development, 2016, 25, 1433-1443.	2.1	31
35	Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Scientific Reports, 2019, 9, 10558.	3.3	31
36	Physiological levels of 1alpha, 25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. Journal of Leukocyte Biology, 2002, 71, 641-51.	3.3	31

#	Article	IF	Citations
37	Role of CD34 Antigen in Myeloid Differentiation of Human Hematopoietic Progenitor Cells. Stem Cells, 2008, 26, 950-959.	3.2	30
38	Antisense Inhibition of c-fes Proto-oncogene Blocks PMA-Induced Macrophage Differentiation in HL60 and in FDC-P1/MAC-11 Cells. Blood, 1997, 89, 135-145.	1.4	29
39	Isolation and characterization of a murine resident liver stem cell. Cell Death and Differentiation, 2008, 15, 123-133.	11.2	29
40	Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa. British Journal of Dermatology, 2015, 173, 731-738.	1.5	29
41	Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. European Journal of Haematology, 1993, 50, 141-148.	2.2	28
42	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers, 2021, 13, 4582.	3.7	28
43	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	6.2	27
44	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia, 2018, 32, 438-449.	7.2	26
45	Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Research, 1999, 59, 3803-11.	0.9	26
46	Correlation between differentiation plasticity and mRNA expression profiling of CD34+-derived CD14â^' and CD14+ human normal myeloid precursors. Cell Death and Differentiation, 2005, 12, 1588-1600.	11.2	22
47	Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia, 2009, 23, 997-1000.	7.2	22
48	Bone Marrow-Derived Hematopoietic Cells Undergo Myogenic Differentiation Following a Pax-7 Independent Pathway. Stem Cells, 2010, 28, 965-973.	3.2	22
49	iVar, an Interpretation-Oriented Tool to Manage the Update and Revision of Variant Annotation and Classification. Genes, 2021, 12, 384.	2.4	21
50	Bone marrowâ€“specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood, 2018, 132, 2053-2066.	1.4	20
51	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	4.6	19
52	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. International Journal of Molecular Sciences, 2021, 22, 1906.	4.1	19
53	Eosinophils, but not neutrophils, exhibit an efficient DNA repair machinery and high nucleolar activity. Haematologica, 2007, 92, 1311-1318.	3.5	18
54	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN. Experimental Hematology, 2009, 37, 1176-1185.e21.	0.4	17

#	Article	IF	Citations
55	Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation. Stem Cells and Development, 2018, 27, 225-236.	2.1	17
56	Overexpression of C-kit in a Leukemic Cell Population Carrying a Trisomy 4 and its Relationship with the Proliferative Capacity. Leukemia and Lymphoma, 1993, 9, 495-501.	1.3	16
57	Co-Culture of Hematopoietic Stem/Progenitor Cells with Human Osteblasts Favours Mono/Macrophage Differentiation at the Expense of the Erythroid Lineage. PLoS ONE, 2013, 8, e53496.	2.5	16
58	A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. Blood Cancer Journal, 2016, 6, e439-e439.	6.2	16
59	Inhibition of cell growth by accumulated spermine is associated with a transient alteration of cell cycle progression. Life Sciences, 1996, 58, 2065-2072.	4.3	15
60	Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. Frontiers in Pharmacology, 2018, 9, 196.	3.5	15
61	Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells. Peptides, 2003, 24, 1207-1220.	2.4	14
62	Transcriptional profiles in melanocytes from clinically unaffected skin distinguish the neoplastic growth pattern in patients with melanoma. British Journal of Dermatology, 2007, 156, 62-71.	1.5	14
63	Abnormal expression patterns ofWT1-as, MEG3andANRILlong non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	1.3	14
64	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. International Journal of Molecular Sciences, 2017, 18, 145.	4.1	14
65	Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. Experimental Hematology, 2012, 40, 1043-1054.e6.	0.4	13
66	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	1.8	13
67	Antisense inhibition of c-fes proto-oncogene blocks PMA-induced macrophage differentiation in HL60 and in FDC-P1/MAC-11 cells. Blood, 1997, 89, 135-45.	1.4	13
68	Presence of a functional vitamin D receptor does not correlate with vitamin D3 phenotypic effects in myeloid differentiation. Cell Death and Differentiation, 1997, 4, 497-505.	11.2	12
69	Gene expression profile of Vitamin D3 treated HL60 cells shows an incomplete molecular phenotypic conversion to monocytes. Cell Death and Differentiation, 2002, 9, 1185-1195.	11.2	12
70	Requirement of the coiled-coil domains of p92c-Fes for nuclear localization in myeloid cells upon induction of differentiation. Oncogene, 2003, 22, 1712-1723.	5.9	12
71	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	1.4	12
72	Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for,CALR-mutated MPNs. Blood Advances, 2021, 5, 2184-2195.	5.2	12

#	Article	IF	Citations
73	The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. Oncotarget, 2016, 7, 45429-45443.	1.8	12
74	Ratios between the abundance of messenger RNA and the corresponding protein of two growth-related genes, c-myc and vimentin, in leukemia blast cells. Cancer Research, 1990, 50, 1988-91.	0.9	12
75	Preclinical study for treatment of hypospadias by advanced therapy medicinal products. World Journal of Urology, 2020, 38, 2115-2122.	2.2	11
76	Antisense Strategies to Characterize the Role of Genes and Oncogenes Involved in Myeloid Differentiationa. Annals of the New York Academy of Sciences, 1992, 660, 11-26.	3.8	10
77	Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis. Npj Precision Oncology, 2021, 5, 4.	5.4	10
78	Antisense Inhibition of Bax mRNA Increases Survival of Terminally Differentiated HL60 Cells. Oligonucleotides, 1998, 8, 341-350.	4.3	9
79	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. Molecular Medicine, 2017, 23, 235-246.	4.4	9
80	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	3.7	9
81	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
82	Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1990, 1, 543-8.	0.8	8
83	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. Cytotherapy, 2017, 19, 1447-1461.	0.7	7
84	Characterization of New ATM Deletion Associated with Hereditary Breast Cancer. Genes, 2021, 12, 136.	2.4	7
85	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 9159.	4.1	7
86	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. Cells, 2022, 11, 1003.	4.1	7
87	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 5242.	4.1	7
88	Terminal Differentiation. Annals of the New York Academy of Sciences, 1992, 663, 180-186.	3.8	6
89	Proliferation, Differentiation Arrest, and Survival in Leukemic Blast Cells. Annals of the New York Academy of Sciences, 1992, 663, 202-214.	3.8	6
90	A functionally active RARÎ± nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. Cell Death and Differentiation, 2001, 8, 70-82.	11.2	6

#	Article	IF	Citations
91	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	5.1	6
92	Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol. International Journal of Molecular Sciences, 2020, 21, 7366.	4.1	6
93	Wnt/CTNNB1 Signal Transduction Pathway Inhibits the Expression of ZFP36 in Squamous Cell Carcinoma, by Inducing Transcriptional Repressors SNAI1, SLUG and TWIST. International Journal of Molecular Sciences, 2020, 21, 5692.	4.1	6
94	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, 11, 113.	5.1	6
95	Detection of low abundance mRNA of myeloid specific genes in cells of acute and chronic lymphoid leukemias by cRNA hybridization. Leukemia, 1990, 4, 688-93.	7.2	6
96	Overexpression of the MPO gene occurring in a case of APL without unusual genotypic characteristics. Leukemia Research, 1990, 14, 735-742.	0.8	4
97	Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework. Diagnosis, 2022, 9, 115-122.	1.9	3
98	Antisense Inhibition of c-fes Proto-oncogene Blocks PMA-Induced Macrophage Differentiation in HL60 and in FDC-P1/MAC-11 Cells. Blood, 1997, 89, 135-145.	1.4	3
99	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. Oncotarget, 2018, 9, 21758-21769.	1.8	3
100	Antisense strategies in leukemia. Haematologica, 1994, 79, 107-11.	3.5	3
101	SOX2 Is a Univocal Marker for Human Oral Mucosa Epithelium Useful in Post-COMET Patient Characterization. International Journal of Molecular Sciences, 2022, 23, 5785.	4.1	3
102	Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera. Blood, 2008, 112, 179-179.	1.4	2
103	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	1.4	2
104	Role of c-fes protooncogene in myeloid differentiation. Cell Death and Differentiation, 1995, 2, 155-62.	11.2	2
105	Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells. Blood, 2018, 132, 4332-4332.	1.4	1
106	Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood, 2011, 118, 3852-3852.	1.4	1
107	Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFÎºB. Blood, 2016, 128, 1203-1203.	1.4	1
108	Purinergic Signaling Modulates Human Bone Marrow-Derived Mesenchymal Stem Cells Function.. Blood, 2009, 114, 1441-1441.	1.4	1

#	Article	IF	Citations
109	Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms. Blood, 2021, 138, 56-56.	1.4	1
110	Magnesium favors the capacity of vitamin D3 to induce the monocyte differentiation of U937 cells. Magnesium Research, 2021, 34, 114-129.	0.5	1
111	Expression and function of nerve growth factor and nerve growth factor receptors on cultured normal human keratinocytes. Journal of Dermatological Science, 1993, 6, 14.	1.9	0
112	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. Blood, 2005, 106, 1730-1730.	1.4	0
113	Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34â^' cell Population with Intrinsic Resistance to IMATINIB Treatment. Blood, 2008, 112, 4221-4221.	1.4	0
114	Purinergic Signaling Differentially Modulates Normal and Leukemic Hematopoiesis.. Blood, 2009, 114, 1436-1436.	1.4	0
115	Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera.. Blood, 2009, 114, 3896-3896.	1.4	0
116	Purinergic Stimulation of Human Bone Marrow-Derived Mesenchymal Stem Cells Modulate Their Function and Differentiation Potential.. Blood, 2010, 116, 3848-3848.	1.4	0
117	C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,. Blood, 2011, 118, 3386-3386.	1.4	0
118	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.	1.4	0
119	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. Blood, 2012, 120, 2854-2854.	1.4	0
120	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	1.4	0
121	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	1.4	0
122	Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors. Blood, 2013, 122, 2712-2712.	1.4	0
123	C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf. Blood, 2014, 124, 5124-5124.	1.4	0
124	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. Blood, 2014, 124, 1867-1867.	1.4	0
125	Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis. Blood, 2015, 126, 2830-2830.	1.4	0
126	MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis. Blood, 2016, 128, 3132-3132.	1.4	0

#	Article	IF	Citations
127	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 4272-4272.	1.4	0
128	Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 1777-1777.	1.4	0
129	Absence of Calreticulin Phenocopies Cellular Abnormalities Induced By Calreticulin Exon-9 Mutation in Myeloproliferative Neoplasms. Blood, 2018, 132, 1780-1780.	1.4	0
130	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. Leukemia Research, 2021, 111, 106747.	0.8	0